Accompanying study in a physician-initiated phase II clinical trial of anti-PD-1 antibody therapy for relapsed / progressive meningioma.

Accompanying study in a physician-initiated phase II clinical trial of anti-PD-1 antibody therapy for relapsed / progressive meningioma. - Accompanying study in MENIVO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036642

Enrollment

Registered

2019-05-07

Start date

2019-05-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

meningioma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients included in MENIVO trial. patients who agree to be enroll in this study.

Exclusion criteria

Exclusion criteria: patients who decline to be enroll in this study.

Design outcomes

Primary

Measure	Time frame
Ratio of methylation, aberrant in expression of mRNA or protein, expression of serum miRNA in meningioma showed effectiveness with nivolumab.	—

Secondary

Measure	Time frame
Genetic features in recurrent / progressive meningioma Natural history of the tumor after the treatment of nivolumab for 1.5years.	—

Countries

Japan

Contacts

Public ContactDai Kamamoto

Keio University School of Medicine Department of Neurosurgery

daikamamoto@hotmail.com03-5363-3808

Outcome results